You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ):子公司將自研平台Smartkine部分專利授權Xilio
格隆匯 02-19 08:39

格隆匯2月19日丨奧賽康(002755.SZ)宣佈,為進一步加速創新研發,推動公司自有研發平台實現產品轉化,推進公司國際化,公司子公司Askgene Pharma(簡稱“Askgene”)與Xilio Therapeutics(簡稱“Xilio”)於近日簽訂了《專利授權許可協議》。

根據協議,Askgene將自有研發平台Smartkine(具有全球知識產權的細胞因子改造技術平台)部分專利授權Xilio,許可Xilio在特定靶點開發中使用相關技術專利。此協議在2020年雙方已簽署的《專利技術排他許可協議》基礎上進一步明確了未來的戰略合作內容。

該協議的主要內容包括:

1、許可Xilio在特定產品(以下簡稱“產品”)研發、生產及商業化中使用Askgene持有的Smartkine技術專利。Smartkine系Askgene自主研發,具有自主知識產權的細胞因子改造平台,通過對細胞因子類藥物的工程改造,解決此類藥物成藥性的問題。

2、Xilio在獲得Askgene的專利授權後,向Askgene支付600萬美元不可退還的專利授權首付款;該產品海外獲批上市後,Xilio向Askgene另行支付不可退還的里程碑款,Xilio還將從其實現的年度淨銷售額按照協議約定的比例支付Askgene不可退還的銷售額提成。

3、Askgene獲得該產品用於腫瘤治療適應症在亞太地區(除日本外)的開發、生產及商業化權利。同時保留自身免疫性疾病適應症的優先獲得權。

公司表示,該次合作將加快公司在腫瘤免疫領域的研發管線佈局,推動公司自有研發平台實現產品轉化,有利於共同發揮雙方的研發優勢及推動公司國際化,符合公司創新藥發展戰略。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account